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Abstract
Background. Recipient desensitization using blood group
(BG)-specific immunoadsorption (ABO-IA) has proven to
enable successful kidney transplantation across major ABO
barriers. In this context, the efficiency of non-antigen-
specific (semiselective) IA adsorbers has not yet been
established. The objective of our study was to quantify
anti-A/B antibody depletion by protein A-, peptide ligand-
and anti-human immunoglobulin-based semiselective IA
in comparison to ABO-IA.
Methods. Eight ABO-IA-treated transplant candidates
and 39 patients subjected to semiselective IA for a variety
of different indications outside the context of ABO-
incompatible transplantation were included. Antibody
patterns (IgG, IgG1-4 subclasses, IgM, C4d-fixing reactiv-
ities) were analysed applying conventional agglutination
testing and flow cytometry.
Results. As assessed by sensitive flow cytometric antibody
detection, ABO-IA-based desensitization led to a profound
even though often incomplete reduction of anti-A/B reactiv-
ities. Persistent complement- or non-complement-fixing re-
activities, however, were not associated with transplant
rejection or capillary C4d deposition. Single sessions of semi-
selective IA turned out to be more effective than ABO-IA in
decreasing levels of anti-A/B IgG [median reduction to 28
versus 59% (ABO-IA) of baseline values, P < 0.001). In
contrast, BG-specific IgM (74 versus 30%, P < 0.001) and
IgG3 (72 versus 42%, P < 0.05) were reduced to a lesser
extent, without differences between tested adsorber types.
Analysis of four consecutive IA sessions revealed that infe-
rior efficiency could not be overcome by serial treatment.
Conclusion. Our observation of limited adsorption capaci-
ties regarding distinct BG-specific Ig (sub)classes suggests
caution in applying semiselective IA techniques in ABO-
incompatible kidney transplantation.
Keywords: ABO incompatibility; immunoadsorption; kidney
transplantation; recipient desensitization
Introduction
ABO incompatibility represents a major immunological
barrier to transplantation [1]. In recent years, several
plasmapheresis- or immunoadsorption (IA)-based desensi-
tization protocols were reported to allow for successful
ABO-incompatible kidney transplantation [1–3].
One major advantage of IA over plasmapheresis may be its
capability to deplete large amounts of circulating antibodies
without considerable losses of essential plasma constituents
[4, 5]. Currently, blood group (BG) antigen-specific apheresis
(ABO-IA) represents the IA technique of choice to remove
anti-A/B antibodies [2, 6, 7]. However, ABO-IA adsorbers
are licensed for single use only, and a need for repeated treat-
ment implies excessive treatment costs (~30 000 USD for
seven treatments). In this respect, the use of regenerative
 The Author 2011. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.
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semiselective IA techniques for non-antigen-specific im-
munoglobulin (Ig) depletion could represent an attractive
less costly alternative (12 000–18 000 USD for a pair of
reusable columns) [4, 5]. Another potential advantage
may be that unselective antibody removal could be bene-
ficial for transplant candidates with additional anti-human
leukocyte antigen (HLA) sensitization [8, 9].
Previous studies have demonstrated efficient removal of
isoagglutinins by semiselective IA in red cell aplasia fol-
lowing ABO-mismatched bone marrow transplantation
[10]. However, there is so far only scarce data on ABO-
incompatible kidney transplantation. Recently, Tyden et al.
[4] reported the occurrence of antibody-mediated rejection
(AMR) in a small series of ABO-incompatible transplant
recipients subjected to IA with protein A. In one of three
patients, antibody removal seemed incomplete using this
modality [4]. This initial experience suggests that it may be
first necessary to carefully dissect the capacity of this and of
related techniques to remove BG-specific antibodies before
considering their use in a clinical setting.
The present study was designed to clarify the impact of
semiselective IA on anti-A/B reactivity patterns in direct
comparison with ABO-IA. For detailed and sensitive as-
sessment of antibody kinetics, we extended our analysis to
flow cytometric detection of anti-A/B antibody binding and
in vitro complement activation.
Materials and methods
Study design and patients
The present prospective study, which was designed to assess the extent of
anti-A/B antibody removal by selective versus semiselective IA, was car-
ried out in accordance with the Helsinki Declaration and approved by the
ethics committee of the Medical University Vienna (EK Nr. 984/2009).
Comparator group. We included eight ABO-incompatible living-
donor renal transplantation candidates subjected to serial sessions
(5–10 treatment sessions >1–2 weeks) of ABO-IA (Glycosorb ABO
A- or B-columns; Glycorex Transplantation AB, Lund, Sweden) to
reduce anti-A/B antibody titers to 1:8 [11]. All patients received a
single dose of rituximab (375 mg/m2 4 weeks before transplantation)
and intravenous immunoglobulin (IVIG, 0.5 g/kg 4–7 days before trans-
plantation; KIOVIG, Baxter Healthcare S.A., Lessines, Belgium). Basal
immunosuppression [tacrolimus (initial trough levels: 12–15 ng/mL),
mycophenolate mofetil (MMF; 2 3 1 g/day) and steroids] was initiated
2 weeks before transplantation. Seven patients were transplanted after
successful desensitization (three living-related and four spousal trans-
plants; A1 into O: N¼ 3, A2 into O: N¼ 2, A1 into B: N¼ 1, B into A1:
N ¼ 1). Clinical outcomes were excellent (100% 1-year graft survival;
no rejection).
Study of single IA sessions. In this first analysis, the eight ABO-IA-
treated transplant candidates were analysed in comparison to 30 patients
subjected to one of three different semiselective apheresis modalities
(10 subjects per modality): (i) IA with staphylococcal protein A (ProtA-
IA; Immunosorba, Fresenius Medical Care, Bad Homburg, Germany),
(ii) IA with synthetic peptide GAM146 (GAM-IA; Globaffin; Fresenius
Medical Care) and (iii) IA with immobilized polyclonal sheep antibodies
against human Ig (Ig-IA; Therasorb Ig; Miltenyi Biotec GmbH, Bergisch
Gladbach, Germany). Semiselective IA was applied outside the context of
ABO-incompatible transplantation [treatment of AMR (typical morpho-
logical features; capillary C4d deposition; Luminex-based solid-phase
detection of donor-specific HLA class I and/or II antibodies) after ABO-
compatible kidney (n ¼ 3) or heart transplantation (n ¼ 1); desensitization
of allosensitized kidney transplant candidates: n ¼ 2; systemic lupus er-
ythemathosus: n ¼ 9; myasthenia gravis: n ¼ 6; multiple sclerosis: n ¼ 2;
other autoimmune diseases: n ¼ 7]. At the time of IA treatment, 8 patients
received immunosuppressive monotherapy (azathioprine or steroids),
10 patients dual therapy (steroids plus azathioprine, mycophenolic acid
or cyclophosphamide) and four calcineurin inhibitor- or mammalian target
of rapamycin inhibitor-based triple therapy.
Study of repeated IA. This analysis was designed to quantify antibody
depletion by four repetitive IA sessions. Six ABO-IA-treated patients
(two patients were excluded because of IVIG infusion already before the
fourth treatment session and thus potential interference of infused anti-A/B
antibodies with test results) were analysed in comparison to a group of nine
patients subjected to treatment with either ProtA-IA (n ¼ 7) or the related
principle of GAM-IA (n ¼ 2). Treatment indications were AMR (n ¼ 7) or
desensitization of sensitized kidney transplant candidates (n ¼ 2).
IA therapy
Plasma (8 L per session) was separated by centrifugation (Cobe Spectra
Apheresis System) under regional citrate anticoagulation, with or without
systemic heparin. For ABO-IA, separated plasma was passed through a
single use absorber. For Prot-IA, GAM-IA and Ig-IA, plasma was pumped
alternating through a regenerative twin column system using an Adasorb
device (Medicap, GmbH, Ulrichstein, Germany).
Haemagglutination testing
Anti-A/B antibody titres were determined by direct agglutination (DA)
at 22C and indirect anti-human globulin testing (IAT) at 37C using
A1, A2 or B test red blood cells (RBC) (DiaMed, Cressier, Switzerland)
and neutral gel cards or gel cards containing rabbit anti-human IgG,
respectively (DiaMed). Tests were performed according to the manu-
facturer’s instructions. The titre was recorded as the inverted value of
the highest plasma dilution that gave a weak (11) agglutination reac-
tion. An influence of irregular red cell antibodies was excluded as
detailed earlier [12].
Flow cytometry
RBC obtained from healthy volunteers (blood type A1, A2, B or O)
were fixed in Karnovsky buffer to prevent agglutination [13–15].
Heparinized blood obtained from healthy volunteers was washed with
phosphate-buffered saline (PBS), and 100 lL of RBC suspension (hae-
matocrit 80–90%) were fixed for 30 min (4C) in 4 mL Karnovsky
buffer (0.2% glutaraldehyde and 1.8% formaldehyde in phosphate buf-
fer, pH 7.4). RBC were washed and re-suspended in PBS containing
0.6% bovine serum albumin (BSA). All subsequent steps were per-
formed at 4C.
For detection of anti-A/B IgG and IgM, 5 lL fixed RBC (1% suspen-
sion) were incubated with 7 lL serum for 30 min. After washing with
Ca21–Mg21-free Hank’s balanced salt solution containing 0.1% BSA,
RBC were stained for 30 min with saturating concentrations of DyLight
649-conjugated rabbit F(ab’)2 anti-human IgG Fcc (Jackson ImmunoRe-
search Europe, Newmarket, UK) or DyLight 649-conjugated Fab goat
anti-human IgM Fc (Jackson ImmunoResearch), respectively.
For IgG subclass detection, RBC were incubated with saturating con-
centrations of mouse anti-human IgG1 (clone HP 6069; Invitrogen
GmbH, Lofer, Austria), IgG2 (clone HP 6002; Invitrogen GmbH),
IgG3 (clone HP 6050; Southern Biotech, Birmingham, AL), or IgG4
(clone HP 6023; Millipore, Temecula, CA), respectively. After 30 min
incubation, cells were washed and incubated for 30 min with DyLight
649-conjugated donkey F(ab’)2 anti-mouse IgG (H 1 L) (Jackson
ImmunoResearch).
For detection of antibody-triggered C4d complement split product dep-
osition, we applied a modified protocol. Following 30 min incubation of
5 lL fixed RBC with 7 lL test serum, 36 lL of a BG-AB serum obtained
from a healthy male volunteer (source of intact human complement) were
added. After another 30 min incubation cells were washed and stained with
DyLight 549-conjugated rabbit anti-human C4d (Biomedica, Vienna,
Austria) for 30 min, 4C.
Samples were analysed using a BD FACSCanto flow cytometer
(Becton Dickinson, Franklin Lakes, NJ). Results were recorded as
normalized mean fluorescence intensity [MFInorm ¼ MFI(test RBC) 
MFI(type O control RBC)]. For IgG subclass binding and C4d fixation, test
thresholds were defined according to MFInorm obtained with three AB
sera from healthy male volunteers. A test result was considered as being
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positive if the MFInorm was above the mean MFInorm 1 2 SDs detected
for control sera.
For flow cytometric detection of anti-A/B IgG, IgG subclasses and
IgM, sera were diluted 1:5 in PBS to prevent saturation and facilitate
assessments of antibody levels in the range relevant for ABO-incompatible
transplantation [16]. In addition, dilution prevented false low results
caused by the prozone effect. Indeed, we frequently observed an increase
in detected antibody levels following in vitro dilution of test sera. In
parallel, in some patients, flow cytometric analysis of undiluted (but not
1:5 diluted) sera revealed an increase in antibody levels during IA therapy
(data not shown). The prozone effect was not observed for in vitro C4d
detection (data not shown). Here, we evaluated undiluted sera.
Immunohistochemistry
All ABO-incompatible kidney transplants underwent protocol biopsies
one week post-transplantation. C4d was stained on paraffin sections
[17]. Biopsies were classified as C4d positive if there was linear C4d
deposition in at least 10% of peritubular capillaries.
Statistics
We applied Mann–Whitney U, Wilcoxon signed-rank, Fisher’s exact or
Spearman correlation tests, as appropriate. A two-sided P-value<0.05 was
considered statistically significant. Statistical calculations were performed
using SPSS for Windows, version 15.0 (SPSS Inc., Chicago, IL).
Results
Anti-A/B antibody depletion by single sessions of
selective versus semiselective IA
To assess BG-specific antibody depletion by a single ses-
sion of selective versus semiselective IA (first session of a
treatment cycle), we included 8 ABO-IA-treated transplant
candidates and 30 patients treated with semiselective IA
for indications outside the context of ABO-incompatible
transplantation.
Baseline immunological results (evaluation of 73 indi-
vidual anti-A/B reactivities) are shown in Table 1.
A comparative analysis of agglutination- versus flow cy-
tometry-based antibody detection revealed significant,
although imperfect, correlations of IAT titers with IgG
MFInorm (r ¼ 0.795, P < 0.001) and DA titers with IgM
MFInorm (r ¼ 0.627, P < 0.001). IgG1 was the most
common BG-reactive IgG subclass, followed by IgG3,
IgG2 and IgG4 (Table 1). Only a minor proportion of
anti-A/B reactivities (22%) had C4d-fixing ability. As
shown in Table 1, among patients treated with semiselec-
tive IA the plasma volumes processed per body weight
were slightly higher than those in ABO-IA-treated pa-
tients. With the exception of IgG3 (higher MFInorm in
ABO-IA-treated patients), baseline immunological re-
sults did not significantly differ between IA treatment
groups (Table 1).
Antibody depletion by different IA techniques is illus-
trated in Figure 1. While ABO-IA did not, or only slightly,
reduce total IgG and IgM concentrations {reduction to
94% [interquartile range (IQR): 89–99] and 93% (85–
98)] of baseline levels}, semiselective IA reduced IgG
to 37% (median, IQR: 26–49%) and IgM to 65% (58–
75%) of pre-IA levels. ABO-IA more effectively reduced
IAT and DA titres. Semiselective IA was more effective in
depleting flow cytometric anti-A/B IgG [reduction to 28%
Table 1. Baseline (pre-IA) immunological data obtained in 38 patients subjected to single sessions of IA treatment
ABO-IA (8 patients) Semiselective IA (30 patients) P-value
Processed plasma volume, mL/kg body weight, median (IQR) 101 (91–111) 117 (103–138) 0.04
Tested reactivities (N) 15 58
Anti-A1, n 7 16
Anti-A2, n 7 16
Anti-B, n 1 26
Total IgG, mg/dLa, median (IQR)b 850 (679–1078) 627 (422–952) 0.3
Total IgM, mg/dLa, median (IQR)b 53 (38–96) 81 (57–102) 0.5
IAT, median titre (IQR)b 1:8 (1:1–1:64) 1:8 (1:2–1:32) 0.8
DA, median titre (IQR)b 1:4 (1:1–1:8) 1:8 (1:2–1:16) 0.5
Flow cytometric anti-A/B reactivities
IgG
MFInorm, median (IQR)
b 23 837 (3677–88 498) 16 099 (3882–46 097) 0.6
IgM
MFInorm, median (IQR)
b 5877 (2997–15 529) 3920 (1222–9901) 0.15
IgG1
Positive result, n (%) 8 (53) 28 (48) 0.8
MFInorm, median (IQR)
b 5153 (2584–8060) 1418 (383–10 069) 0.09
IgG2
Positive result, n (%) 4 (27) 17 (29) >0.99
MFInorm, median (IQR)
b 21 375 (14 763–69 686) 18 656 (9747–45 454) 0.6
IgG3
Positive result, n (%) 7 (47) 26 (45) >0.99
MFInorm, median (IQR)
b 7692 (3872–34 127) 2113 (745–2969) <0.001
IgG4
Positive result, n (%) 1 (7) 5 (9) >0.99
MFInorm, median (IQR)
b 2675 2262 (1389–2335) c
C4d
Positive result, n (%) 3 (20) 13 (22) >0.99
MFInorm, median (IQR)
b 704 (1386–1682) 750 (410–1052) 0.19
aIg concentrations were assessed by nephelometry (reference values for IgG: 700–1600 mg/dL; IgM: 40–230 mg/dL).
bMedian and IQR are given only if sample sizes were 4.
cNo statistical comparison because of insufficient samples sizes.
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(IQR: 22–49) versus 59% (43–96) of baseline levels, P <
0.001] but less effective regarding anti-A/B IgM depletion
[74% (IQR: 61–97) versus 30% (IQR: 22–45), P <
0.001]. Interestingly, there were no differences between
the three tested semiselective adsorber types (Figure 1).
Another remarkable finding was that ABO-IA also low-
ered ABO reactivities not directed against the BG antigens
of applied columns [IgG: 80% (41–95); IgM: 74% (38–
118) of baseline MFInorm].
Semiselective IA was superior (GAM-IA) or at least
equally effective (ProtA-IA, Ig-IA) with respect to BG-
specific IgG1 depletion (Table 2). In contrast, semiselective
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Fig. 1. Antibody depletion by single sessions of ABO-IA in comparison to semiselective IA modes. Levels of (A) total IgG and (B) total IgM were
assessed by nephelometry (normal reference values for IgG: 700–1600 mg/dL; IgM: 40–230 mg/dL). Agglutination testing was performed using gel
cards for (C) IAT or (D) DA. IgG (E) and IgM (F) anti-A/B reactivities were quantified by flow cytometry. Results are given as percentages of baseline
(pre-IA) levels. Only ABO column BG-specific reactivities were considered for calculation and presentation of results obtained with ABO-IA. Results are
presented as box plots indicating median, IQR and range. Mild outliers are indicated as open dots, extreme outliers as asterisks. For statistical
comparisons, non-parametric testing (Mann–Whitney U-test) was applied.
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adsorbers turned out to be less effective regarding IgG3
elimination. For IgG2, no significant differences were ob-
served, and there were no major numerical differences
between different adsorber types with respect to kinetics
of IgG4 and C4d-fixing reactivities (Table 2).
Differing levels of immunosuppression among patients
subjected to semiselective IA did not influence the extent
of anti-A/B antibody depletion. Subjects receiving two or
more immunosuppressive compounds did not differ from
patients receiving one or no compound [anti-A/B IgG: re-
duction to 37% (median, IQR: 23–45) versus 27% (20–51);
anti-A/B IgM: 72% (56–89) versus 75% (66–108),
respectively].
Anti-A/B antibody depletion by repetitive treatment with
selective versus semiselective IA
In a second analysis, we evaluated antibody depletion by
four subsequent IA sessions (Supplementary table 1). Six
ABO-IA-treated patients (two of the eight ABO-IA-treated
patients were excluded from this analysis because of IVIG
infusion before the fourth IA session) were analysed in
comparison to nine patients subjected to semiselective
IA. Again, repeated semiselective IA tended to be more
effective than ABO-IA regarding anti-A/B IgG depletion
but was significantly less effective in reducing BG-specific
IgM and IgG3 (Supplementary table 1).
Anti-A/B antibody depletion upon ABO-IA-based
recipient desensitization
Successful ABO-IA-based recipient desensitization (seven
of the eight ABO-incompatible transplant candidates) was
associated with a decrease in levels of flow cytometric
donor BG-specific IgG and IgM reactivities to 31% (IQR:
15–108) and 21% (12–38) of baseline values. We observed
a transient increase of anti-A/B reactivities following ad-
ministration of IVIG, despite infusion during IA treatment.
In 4 patients, anti-A/B IgG (12 tested BG-specific reactiv-
ities) was quantified shortly before and after IVIG infusion.
Before treatment, IgG levels were 37% (median, IQR:
21–54), after IVIG treatment 56% (IQR: 29–155) of pre-
IA baseline levels (P ¼ 0.01). Immediately before trans-
plantation, two patients still showed significant levels of
BG-specific IgG subclass reactivity (Table 3). One of them
tested positive for both IgG1 and IgG3, whereas another
patient became weakly IgG4 positive, possibly due to IVIG
treatment. A third patient had C4d-fixing reactivity without
significant IgG subclass binding. Three of the seven ABO-
incompatible transplants showed subclinical capillary C4d
deposition in early protocol biopsies. They did not differ
from C4d-negative patients regarding BG-specific IgG and
IgM levels immediately before transplantation (not shown).
The two individuals who tested positive for complement-
binding IgG subclasses (IgG1 and 3) or in vitro C4d fix-
ation were C4d negative (Table 3).
Discussion
The present study, which was designed to investigate the
effect of different IA modalities on BG-specific reactivity
patterns, revealed inferior anti-A/B IgM and IgG3 deple-
tion by semiselective IA.
Regarding incomplete IgM elimination, our results are in
accordance with earlier reports [18]. Interestingly, there were
no meaningful differences between different types of semi-
selective adsorbers, a finding which may be in some contrast
to one previous large study suggesting more pronounced
total IgM depletion by Ig-IA [18]. However, there are also
other studies that failed to demonstrate such differential ef-
fects [19, 20]. In contrast to IgM, semiselective IA was
highly effective regarding depletion of anti-A/B IgG. Semi-
selective techniques were even more efficient than ABO-IA,
but this may be at least partly explained by the slightly
higher plasma volumes treated per body weight. Our finding
of inferior IgG3 depletion by ProtA-IA and GAM-IA is in
accordance with previous studies [20, 21]. However, we
have no good explanation for a similar inferiority of Ig-IA,
which may be in some contrast to earlier data [20].
Interestingly, differential effects of IA techniques on
Ig (sub)class patterns did not result in major differences
regarding complement-fixing abilities of detected reactiv-
ities. One possible explanation could be the predominance
of complement-activating IgG1 (binding intensity and fre-
quency), which may have overwhelmed differential effects
on IgG3 and/or IgM.
In clinical routine, haemagglutination tests are widely
used for anti-A/B antibody detection. Major pitfalls of ag-
glutination testing may be marked inter-centre variabilities
and the disadvantage of only semiquantitative estimation of
Table 2. Reduction of ABO-BG-specific IgG subclasses and C4d-fixing reactivities by single IA sessions
IgG1 IgG2 IgG3 IgG4 C4d fixation
Reactivity after IA treatment, median percentage of baseline MFInorm (IQR)
a,b
Selective IA
ABO-IA (8 patients) 56 (38–66) 29 (21–75) 42 (30–53) 81 57, 75, 88
Semiselective IA
Prot-IA (10 patients) 51 (0–172) 42 (21–59) 70 (61–88)* 72, 90 73 (58–85)
GAM-IA (10 patients) 20 (7–40)* 25 (23–29) 80 (61–97)** 76 50 (46–54)
Ig-IA (10 patients) 20 (0–105) 29 (22–33) 67 (49–82)* 68, 92 90, 93
aMFInorm values were recorded only for reactivities above the threshold defined in the methods section.
bMedian and IQR are given only if sample sizes were 4.
*P < 0.05 (non-parametric comparison to the results obtained with ABO-IA).
**P < 0.01 (non-parametric comparison to the results obtained with ABO-IA).
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antibody levels [22, 23]. Recently, flow cytometric anti-
A/B antibody detection was suggested to allow for more
accurate and reproducible quantification of BG reactivities
[14, 16]. In line with a previous study [16], we found sig-
nificant correlations between flow cytometric IgG or IgM
detection and the results of IAT or DA, respectively. How-
ever, as evidenced by r values <0.8, the level of test con-
cordance was far from perfect. In this respect, a remarkable
observation was the differing impact of semiselective IA on
the results of IAT (less pronounced reduction in a compar-
ison to ABO-IA) versus IgG detection by flow cytometry
(more pronounced reduction). One can speculate that this
phenomenon resulted from an influence of IgM-induced
agglutination on the results of IAT.
However, there may also be some drawbacks with the
use of flow cytometric antibody detection. It is important to
note that changes in recorded MFI values may not simply
reflect reductions in antibody concentrations but may be
influenced by a variety of additional factors, such as indi-
vidual levels of antibody avidity and affinity. Moreover, the
definition of cut-off values may be a major challenge.
While in earlier studies, one AB serum was used for neg-
ative control and/or threshold definition [13–15, 16], we
have included three different AB control sera to better
account for variations in background levels. Nevertheless,
we are aware of the limitations of this approach and one can
expect further improvement of test performance by includ-
ing a larger number of control samples. A major technical
caveat may be test artefacts caused by in vitro agglutina-
tion. However, there are several strategies to prevent
agglutination, such as the use of dilute RBC [16] or, as in
our study, fixation of RBC [13–15]. Moreover, evaluating
undiluted sera, we found that test results were frequently
affected by the prozone effect. This phenomenon has been
described for a variety of different in vitro test systems
including ABO and HLA antibody detection and was sug-
gested to be caused by interfering IgM or C1 [24, 25]. Our
results reinforce that strategies to overcome this phenomenon,
such as standardized serum dilution (e.g. 1:5, as in our study),
are necessary to avoid false low results. Another advantage of
serum dilution may be that it prevents early saturation of high
titre sera and allows for full assessments in the range relevant
for ABO-incompatible transplantation [16].
A detailed knowledge of pathogenetic properties of anti-
body patterns may provide a useful basis for decision mak-
ing regarding the choice of the IA device. For example, in
dilated cardiomyopathy, a primordial role of IgG3 type
autoantibodies has suggested the preferential use of IA
schedules allowing for more efficient IgG3 elimination
[20]. However, the relative contribution of different Ig
(sub)classes to AMR after ABO-incompatible transplants
is less well understood. In this specific context, the predic-
tive value of baseline IgG and/or IgM ABO antibody levels
has been controversially discussed. In an initial study of
plasmapheresis-based desensitization, maximum pre-trans-
plant IgG but not IgM agglutination titres were associated
with rejection [26]. However, in a subsequent study of ta-
crolimus/MMF-treated patients, such associations could no
longer be observed [27]. There is only scarce data regarding
the role of anti-A/B antibody levels detected immediately
before transplantation. Sensitive flow cytometric antibodyT
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detection has uncovered persistent levels of pre-transplant
reactivity (below the threshold defined according to aggluti-
nation testing) in our as well as in a previous study [15],
without any impact on transplant outcomes. Interestingly,
there was also no relationship between residual (comple-
ment-fixing) ABO reactivity and (subclinical) capillary
C4d deposition, a common feature, which was earlier sug-
gested to reflect a state of transplant accommodation [28].
Regarding ABO-IA, an interesting observation was a
certain level of non-specificity, as suggested by some re-
duction also of reactivities to BG antigens not covered by
the applied ABO-IA adsorber. A similar effect has been
described in an earlier report and was suggested to result
from antibody cross-reactivities [15].
There are several limitations to our study, including a
marked heterogeneity regarding baseline immunosuppres-
sive therapy between ABO-IA-treated and semiselective
IA-treated patients. One can argue that differences in anti-
body depletion could at least partly be due to these imbal-
ances. However, addressing this issue, we could not identify
a major influence of concomitant immunosuppressive
therapy on the kinetics of antibody levels. Another draw-
back of our study was that for some of the studied reactiv-
ities, such as IgG4, sample sizes were too small to allow for
valid statistical comparison.
In conclusion, our present study demonstrates high effi-
ciency of semiselective IA regarding elimination of BG-
specific IgG, but inferiority with respect to IgM and IgG3
depletion. Our study cannot provide definite answers
regarding prevention of AMR in ABO-incompatible trans-
plantation. In this respect, a study limitation may be that we
did not include patients subjected to standard or double-
filtration plasmapheresis, techniques used at many trans-
plant units, especially in the USA and Japan [1, 3]. How-
ever, our results suggest the need of caution in applying
semiselective IA. While it is tempting to speculate that
unselective IgG depletion could be advantageous for pa-
tients with additional HLA sensitization, one can expect
that incomplete anti-A/B antibody depletion (IgM and
IgG3) could in some instances necessitate additional meas-
ures (e.g. plasmapheresis) to achieve adequate antibody
reduction.
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